{"&cites=17893470937361497551&as_sdt=2005&sciodt=0,5&hl=en":[{"title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","url":"https://www.nejm.org/doi/full/10.1056/nejmoa065044","authors":["RJ Motzer","RJ Motzer TE Hutson","RJ Motzer TE Hutson P Tomczak…"],"year":2007,"numCitations":6133,"pdf":"https://www.nejm.org/doi/full/10.1056/nejmoa065044","citationUrl":"http://scholar.google.com/scholar?cites=12674526305022444340&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:NAM1m4X25K8J:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=12674526305022444340&hl=en&as_sdt=2005&sciodt=0,5","publication":"Mass Medical Soc","p":1,"exp":1596876833738},{"title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa066838","authors":["G Hudes","G Hudes M Carducci","G Hudes M Carducci P Tomczak…"],"year":2007,"numCitations":4021,"pdf":"https://www.nejm.org/doi/full/10.1056/NEJMoa066838","citationUrl":"http://scholar.google.com/scholar?cites=11854457709475007825&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:UQ0mqnp-g6QJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=11854457709475007825&hl=en&as_sdt=2005&sciodt=0,5","publication":"Mass Medical Soc"},{"title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","url":"https://www.sciencedirect.com/science/article/pii/S0140673607619047","authors":["B Escudier","B Escudier A Pluzanska","B Escudier A Pluzanska P Koralewski","B Escudier A Pluzanska P Koralewski A Ravaud…"],"year":2007,"numCitations":2570,"pdf":"https://journals.viamedica.pl/nowotwory_journal_of_oncology/article/download/52342/39075","citationUrl":"http://scholar.google.com/scholar?cites=5427817888518646484&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:1Cqqnpx7U0sJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=5427817888518646484&hl=en&as_sdt=2005&sciodt=0,5","publication":"Elsevier"},{"title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3646307/","authors":["RJ Motzer","RJ Motzer TE Hutson","RJ Motzer TE Hutson P Tomczak…"],"year":2009,"numCitations":2287,"pdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3646307/","citationUrl":"http://scholar.google.com/scholar?cites=9930987091739607833&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:GQMhsCT00YkJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=9930987091739607833&hl=en&as_sdt=2005&sciodt=0,5","publication":"ncbi.nlm.nih.gov"},{"title":"EAU guidelines on renal cell carcinoma: the 2010 update","url":"https://www.sciencedirect.com/science/article/pii/S0302283810005919","authors":["B Ljungberg","B Ljungberg NC Cowan","B Ljungberg NC Cowan DC Hanbury","B Ljungberg NC Cowan DC Hanbury M Hora…"],"year":2010,"numCitations":1557,"pdf":"http://www.aamed.eco.br/imagens/pdf/EAU-Guidelines-on-Renal-Cell-Carcinoma-the-2010-Update.pdf","citationUrl":"http://scholar.google.com/scholar?cites=13647781770707630156&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:THgUHzapZr0J:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=13647781770707630156&hl=en&as_sdt=2005&sciodt=0,5","publication":"Elsevier"},{"title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results …","url":"https://confkhalifa.com/trainingkhalifa/wp-content/uploads/2017/05/DP-2-LCA-ARTICLE-The%CC%81o-PEZEL-CB-avril-2017-anglais.pdf","authors":["DYC Heng","DYC Heng W Xie","DYC Heng W Xie MM Regan","DYC Heng W Xie MM Regan MA Warren…"],"year":2009,"numCitations":1433,"pdf":"https://confkhalifa.com/trainingkhalifa/wp-content/uploads/2017/05/DP-2-LCA-ARTICLE-The%CC%81o-PEZEL-CB-avril-2017-anglais.pdf","citationUrl":"http://scholar.google.com/scholar?cites=4181130477325190870&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:1gaHPARcBjoJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=4181130477325190870&hl=en&as_sdt=2005&sciodt=0,5","publication":"confkhalifa.com"},{"title":"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell …","url":"https://ascopubs.org/doi/abs/10.1200/JCO.2004.08.185","authors":["MB Atkins","MB Atkins M Hidalgo","MB Atkins M Hidalgo WM Stadler","MB Atkins M Hidalgo WM Stadler TF Logan…"],"year":2004,"numCitations":1113,"pdf":"/scholar?output=instlink&q=info:xyjnWZHjGXIJ:scholar.google.com/&hl=en&as_sdt=2005&sciodt=0,5&scillfp=205136760801941013&oi=lle","citationUrl":"http://scholar.google.com/scholar?cites=8221852808159635655&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:xyjnWZHjGXIJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=8221852808159635655&hl=en&as_sdt=2005&sciodt=0,5","publication":"ascopubs.org"},{"title":"Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2651074/","authors":["BI Rini","BI Rini S Halabi","BI Rini S Halabi JE Rosenberg…"],"year":2008,"numCitations":1022,"pdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2651074/","citationUrl":"http://scholar.google.com/scholar?cites=18273808260162582187&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:q_aWOMubmf0J:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=18273808260162582187&hl=en&as_sdt=2005&sciodt=0,5","publication":"ncbi.nlm.nih.gov"},{"title":"Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival","url":"https://www.nature.com/articles/nm.2883?page=15","authors":["S Walter","S Walter T Weinschenk","S Walter T Weinschenk A Stenzl","S Walter T Weinschenk A Stenzl R Zdrojowy…"],"year":2012,"numCitations":1013,"citationUrl":"http://scholar.google.com/scholar?cites=17595009171896881605&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:xVGnlp4HLvQJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=17595009171896881605&hl=en&as_sdt=2005&sciodt=0,5","publication":"nature.com"},{"title":"Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma","url":"https://pdfs.semanticscholar.org/1092/47fe886f78deb970c7ae073d686037117406.pdf","authors":["DF McDermott","DF McDermott MM Regan","DF McDermott MM Regan JI Clark…"],"year":2004,"numCitations":874,"pdf":"https://pdfs.semanticscholar.org/1092/47fe886f78deb970c7ae073d686037117406.pdf","citationUrl":"http://scholar.google.com/scholar?cites=16423068880150736622&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:7i4oIyJ26uMJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=16423068880150736622&hl=en&as_sdt=2005&sciodt=0,5","publication":"pdfs.semanticscholar.org"}]}